Yong Hua Gao

Zhengzhou University

SCHOLARLY PAPERS

1

DOWNLOADS

94

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Azurocidin-1 Links Bronchiectasis Severity and Exacerbations Through Impairment of Epithelial Defence and is Targeted by Dipeptidyl Peptidase-1 Inhibition

Number of pages: 24 Posted: 18 Mar 2025
University of Dundee, University of Dundee, University of Dundee, AstraZeneca Pharmaceuticals - UK, University of Dundee, University of Dundee, University of Dundee, University of Dundee, University of Dundee, University of Dundee - Division of Systems Medicine, University of Dundee, Institut d'Investigacions Biomèdiques August Pi Sunyer, University of Dundee, University of Dundee, University of Dundee, Hallym University, Newcastle University - Population Health Sciences Institute, King’s College London, Hannover Medical School - Department of Respiratory Medicine, University Hospitals Leuven - Department of Pneumology, Imperial College London, Imperial College London, University of Dundee, AZ Nikolaas - Department of Respiratory Disease, Government of the United Kingdom - Royal Brompton Hospital, Zhengzhou University, Nanyang Technological University (NTU), C K Birla Hospitals, NHS Foundation Trust - Cambridge Centre for Lung Infection, University of Amsterdam - University Medical Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Respiratory Unit and Cystic Fibrosis Adult Center, Hospital Universitari Vall d'Hebron of Barcelona - Pneumology Department, Carmel Medical Center - Pulmonology Institute and CF Center, AstraZeneca Pharmaceuticals - UK, Insmed Incorporated, Insmed Incorporated, Insmed Incorporated, Insmed Incorporated, Insmed Incorporated, Imperial College London, IRCCS Humanitas Research Hospital, University of Barcelona, University of Dundee and University of Dundee - Division of Molecular and Clinical Medicine
Downloads 94 (604,502)

Abstract:

Loading...

bronchiectasis, COPD, inflammation, neutrophil, mucociliary clearance, chronic respiratory disease, mechanism, respiratory epithelium, microbiome, human challenge model, rhinovirus, phase 2 trial